Resilience is proud to support CARGO Therapeutics' novel allogeneic CAR-T cell therapy
SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to...
NEWS
Read on
Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
San Diego, CA – January 8, 2025 – National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access...
Resilience Announces Appointment of William S. Marth, RPh., MBA as Chief Executive Officer
SAN DIEGO, CA, December 5, 2024 – National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening...
Resilience Secures Funding to Expand Domestic Manufacturing for Critical Pharmaceutical Ingredients
San Diego, CA – October 3, 2024 – National Resilience, Inc., a technology-focused biomanufacturing company dedicated to broadening access to complex...
Resilience Appoints Dr. Susan Billings, Chief Commercial Officer
SAN DIEGO, CA, September 30, 2024 – National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening...
Resilience Expands Clinical and Commercial Drug Product Manufacturing Capabilities and Capacities
$225 million to be invested into Cincinnati facility to increase PFS and Cartridge fill/finish capabilities Expanding Research Triangle Park (RTP)...
